APLN may inhibit the expression of fibroblast growth factor 2 (FGF2) and FGF receptor 1 (FGFR1) by regulating the expression of miR-424 and miR-503, thereby improving PAH [41]. The gene discussed is FGF2; the disease is pulmonary arterial hypertension.